Related Experiment Videos
Changes in human cultured cells exposed to a perfluorocarbon emulsion
Transfusion
|January 1, 1985
Summary
Fluosol-DA, a perfluorocarbon emulsion, caused lasting cell damage and stopped growth in human fibroblast cells. These cytotoxic effects occurred even after the emulsion was removed, raising safety concerns for patient use.
Area of Science:
- Cell Biology
- Toxicology
- Biomaterials
Background:
- Perfluorocarbon emulsions are used in medical applications, including as blood substitutes.
- Understanding the cellular effects of these compounds is crucial for patient safety.
- Previous research has indicated potential biological interactions of perfluorocarbons.
Purpose of the Study:
- To investigate the cytotoxic effects of Fluosol-DA (20%) on human fibroblast cells.
- To determine if Fluosol-DA causes persistent damage and inhibits cell proliferation.
- To assess the morphological changes induced by Fluosol-DA exposure.
Main Methods:
- Human embryonic lung fibroblasts (IMR 90) and SV40-transformed fibroblasts (AG 2804) were exposed to 4% Fluosol-DA in culture medium for 18 hours.
- Cell proliferation was monitored after exposure.
- Morphological changes were observed using microscopy.
- The effects of washing off the emulsion and replacing it with normal medium were assessed.
Main Results:
- Fluosol-DA (20%) induced persistent cytotoxic changes and growth inhibition in both normal and transformed human fibroblasts.
- Cells ceased proliferation and exhibited degenerative changes after 18 hours of exposure.
- Cytotoxicity was observed even after the emulsion was removed and replaced with fresh medium.
- Significant cytoplasmic vacuolation was a prominent morphological manifestation of Fluosol-DA toxicity.
Conclusions:
- Perfluorocarbon emulsions like Fluosol-DA can cause significant and persistent cytotoxicity in human fibroblast cells.
- The observed degenerative changes and growth inhibition raise concerns regarding the clinical application of Fluosol-DA.
- Further research is needed to establish safe dosage limits for perfluorochemical use in patients.